Amgen Inc. (AMGN) FY2024 Annual P&L / Income Statement

Amgen Inc. (AMGN) FY2024 Annual P&L / Income Statement

Income statement for 2024-01-01 through 2024-12-31. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

33,424,000,000 US dollars

Cost of sales

12,858,000,000 US dollars

Gross profit (calculated)

20,566,000,000 US dollars

Operating expenses (calculated)

13,308,000,000 US dollars

Operating income

7,258,000,000 US dollars

Other income (expense), net (calculated)

negative 2,649,000,000 US dollars

Income before income taxes

4,609,000,000 US dollars

Provision for income taxes

519,000,000 US dollars

Net income

4,090,000,000 US dollars

Prolia

4,374,000,000 US dollars

ENBREL

3,316,000,000 US dollars

XGEVA

2,225,000,000 US dollars

Repatha

2,222,000,000 US dollars

Otezla

2,126,000,000 US dollars

TEPEZZA

1,851,000,000 US dollars

EVENITY

1,563,000,000 US dollars

Kyprolis

1,503,000,000 US dollars

Nplate

1,456,000,000 US dollars

Aranesp

1,342,000,000 US dollars

BLINCYTO

1,216,000,000 US dollars

KRYSTEXXA

1,185,000,000 US dollars

Vectibix

1,045,000,000 US dollars

TEZSPIRE

972,000,000 US dollars

Other products

5,630,000,000 US dollars

Other revenues

1,398,000,000 US dollars

Research and development

5,964,000,000 US dollars

Selling, general and administrative

7,096,000,000 US dollars

Other

248,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.